• Something wrong with this record ?

Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia

M. Šíma, P. Pokorná, J. Hartinger, O. Slanař,

. 2018 ; 43 (2) : 196-201. [pub] 20170922

Language English Country England, Great Britain

Document type Journal Article, Observational Study

WHAT IS KNOWN AND OBJECTIVE: Phenobarbital is the first-line treatment of seizures in asphyxiated neonates; however, due to the high pharmacokinetic variability in this population, there is no consensus on the optimal dosage regimen. This study was conducted to identify variables that affect phenobarbital fate during routine clinical care and then to evaluate the dosage schedule that could be applied in term asphyxiated neonates with respect to achieving the target therapeutic range. METHODS: Phenobarbital pharmacokinetics was calculated based on serum concentrations measurements using one-compartmental model. Body weight, body surface area, gestational age, creatinine clearance, total bilirubin, alanine aminotransferase, aspartate aminotransferase, international normalized ratio, Apgar scores, umbilical cord arterial pH and base excess were explored as covariates in linear regression models. Based on this analysis, phenobarbital loading and maintenance dose regimen were projected. RESULTS AND DISCUSSION: In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively. The drug volume of distribution was associated with body weight, length and body surface area, whereas clearance was not in relationship with any explored features. Weight-normalized loading dose of 15 mg/kg and weight-normalized daily maintenance dose of 3 mg/kg proved to be optimal in our study population to reach phenobarbital therapeutic range. WHAT IS NEW AND CONCLUSIONS: This study presents basis for phenobarbital initial dosing in term asphyxiated neonates during first week of life. Phenobarbital weight-normalized loading dose of 15 mg/kg lead to simulated target peak concentrations in 72% of neonates, weight-normalized maintenance dose of 3 mg/kg lead to steady state within therapeutic window in the same proportion of patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033709
003      
CZ-PrNML
005      
20181016103620.0
007      
ta
008      
181008s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jcpt.12632 $2 doi
035    __
$a (PubMed)28940525
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Šíma, M $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
245    10
$a Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia / $c M. Šíma, P. Pokorná, J. Hartinger, O. Slanař,
520    9_
$a WHAT IS KNOWN AND OBJECTIVE: Phenobarbital is the first-line treatment of seizures in asphyxiated neonates; however, due to the high pharmacokinetic variability in this population, there is no consensus on the optimal dosage regimen. This study was conducted to identify variables that affect phenobarbital fate during routine clinical care and then to evaluate the dosage schedule that could be applied in term asphyxiated neonates with respect to achieving the target therapeutic range. METHODS: Phenobarbital pharmacokinetics was calculated based on serum concentrations measurements using one-compartmental model. Body weight, body surface area, gestational age, creatinine clearance, total bilirubin, alanine aminotransferase, aspartate aminotransferase, international normalized ratio, Apgar scores, umbilical cord arterial pH and base excess were explored as covariates in linear regression models. Based on this analysis, phenobarbital loading and maintenance dose regimen were projected. RESULTS AND DISCUSSION: In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively. The drug volume of distribution was associated with body weight, length and body surface area, whereas clearance was not in relationship with any explored features. Weight-normalized loading dose of 15 mg/kg and weight-normalized daily maintenance dose of 3 mg/kg proved to be optimal in our study population to reach phenobarbital therapeutic range. WHAT IS NEW AND CONCLUSIONS: This study presents basis for phenobarbital initial dosing in term asphyxiated neonates during first week of life. Phenobarbital weight-normalized loading dose of 15 mg/kg lead to simulated target peak concentrations in 72% of neonates, weight-normalized maintenance dose of 3 mg/kg lead to steady state within therapeutic window in the same proportion of patients.
650    _2
$a asfyxie $x farmakoterapie $x metabolismus $7 D001237
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gestační stáří $7 D005865
650    _2
$a poločas $7 D006207
650    _2
$a lidé $7 D006801
650    _2
$a mozková hypoxie a ischemie $x farmakoterapie $x metabolismus $7 D020925
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a fenobarbital $x aplikace a dávkování $x farmakokinetika $7 D010634
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a tkáňová distribuce $7 D014018
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Pokorná, P $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Department of Pediatrics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Intensive Care and Department of Pediatric Surgery, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands.
700    1_
$a Hartinger, J $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Slanař, O $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
773    0_
$w MED00007277 $t Journal of clinical pharmacy and therapeutics $x 1365-2710 $g Roč. 43, č. 2 (2018), s. 196-201
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28940525 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181016104117 $b ABA008
999    __
$a ok $b bmc $g 1340263 $s 1030703
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 43 $c 2 $d 196-201 $e 20170922 $i 1365-2710 $m Journal of clinical pharmacy and therapeutics $n J Clin Pharm Ther $x MED00007277
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...